天津医药

• 临床论丛 • 上一篇    下一篇

左西孟旦注射液治疗老年重度心力衰竭的疗效及安全性分析

任古松   

  1. 天津市第五中心医院
  • 收稿日期:2011-10-24 修回日期:2012-06-01 出版日期:2012-11-15 发布日期:2012-11-15
  • 通讯作者: 任古松

Levosimendan injection in treatment of elderly patients with severe heart failure analysis of the efficacy and safety

  • Received:2011-10-24 Revised:2012-06-01 Published:2012-11-15 Online:2012-11-15

PDF (PC)

2550

摘要： 目的 评价对常规治疗（如利尿剂、血管紧张素转换酶抑制剂和洋地黄类药物等）疗效不佳的老年重度失代偿性心力衰竭患者，静脉注射左西孟旦（Levosimendan Injection）的有效性及安全性。方法：40例常规纠正心衰治疗无好转的老年重度心力衰竭患者随机分为试验组（20例，给予左西孟旦治疗）和对照组（20例，给予米力农治疗）。观察两组治疗前后临床症状、BNP和血流动力学改变情况。结果：两组比较，经过治疗，左西孟旦组患者BNP下降、呼吸困难好转方面较米力农组更显著（P﹤0.01），而米力农组患者血压降低则更显著（P﹤0.01）。二者之间在改善心衰症状方面的差异具有显著性（P﹤0.01）。结论：左西孟旦在治疗老年重度心力衰竭患者疗效和安全性均优于米力农。

关键词: 左西孟旦, 米力农, 心力衰竭

Abstract: Objective Evaluation on regular treatment (such as diuretics, angiotensin converting enzyme inhibitor and Digitalis) inefficacy of severe Decompensated congestive heart failure in elderly patients, intravenous injection of Levosimendan (Levosimendan Injection) the effectiveness and safety. Methods General correction of 40 cases of severe congestive heart failure in the elderly patients with heart failure therapy no better randomly divided into Group (20 cases, granting of Levosimendan therapy) and a control group (20 cases, give the metres of milrinone therapy). Observation on the treatment of the two groups, BNP and hemodynamic changes before and after clinical symptoms. Results Comparison of the two groups, after treatment, Levosimendan group BNP loss, difficulty in breathing in patients with improved insight group is more notable than milrinone (p< 0.01), and blood pressure decrease is more pronounced in milrinone Group (p﹤0.01). Between difference in improving the symptoms of heart failure has a significant (p ﹤0.01).. Conclusion: Levosimendan in treatment efficacy and safety are superior to intravenous milrinone in patients with severe heart failure.

Key words: Levosimendan, milrinone, HF